

Accelera Srl Announces Change in Board Composition Effective Today

Nerviano_October_1_2022_Accelera Srl, leading CRO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico Pesenti, effective today. Hugues Dolgos, Pharm.D., CEO of NMS Group, is appointed as Sole Director of Accelera Srl.

###

About Accelera

[Accelera](#) is a premium tier Contract Research Organization (CRO), developing and offering new technologies and integrated programs to pharmaceutical and biotechnology companies around the world to move forward their innovative drug candidates from early discovery to the clinic.

Built on decades as part of the international pharmaceutical industry, Accelera provides specific competence and tools to help Companies in predicting and managing potential pharmacokinetic, metabolic, and toxicity issues, adding real value to Company's R&D programme.

Major services available at Accelera include:

- ✓ High-throughput preclinical profiling and in silico ADMET prediction and modelling;
- ✓ IND/CTA enabling packages, including GLP general toxicology, safety pharmacology, genotoxicity, ADME and pharmacokinetics (PK);
- ✓ Toxicology and ADME/PK studies in rodent and non-rodent species, including Nonhuman Primates (NHP);
- ✓ Bioanalysis and pharmacokinetics for preclinical and clinical studies, including assay development and validation, PK/PD, and population PK data analysis;
- ✓ Drug disposition packages, including the synthesis of radio-labelled compound and QWBA;
- ✓ Preclinical development consultancy and preparation of regulatory documentation.

Accelera currently employs more than 50 scientists and about 55 technical staff skilled in multiple preclinical disciplines (drug safety, pharmacokinetics, bio-analysis, analytical biology, drug metabolism and distribution).

Accelera facilities are fully GLP and AAALAC accredited.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it